Analgesics
Antiandrogens
Antihistamines
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchZenuzolacZenuzolac (more..)
Metformin Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta Thermotherapy Meta
Melatonin Meta

 

Safety, Tolerability and Efficacy and Dose Response of GLS-1027 in the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection

Kane et al., NCT04590547, NCT04590547, Apr 2025
Mortality, -200% Improvement Relative Risk Mortality, 360mg -196% Mortality, 120mg -205% Recovery, -1% Recovery, 360mg -43% Recovery, 120mg 48% Hospitalization time, 1% Hospitalization time, 3.. 1% Hospitalization time, 1.. 1% Zenuzolac  Kane et al.  LATE TREATMENT  DB RCT Is late treatment with zenuzolac beneficial for COVID-19? Double-blind RCT 132 patients in multiple countries Higher mortality with zenuzolac (not stat. sig., p=0.34) c19early.org Kane et al., NCT04590547, April 2025 Favorszenuzolac Favorscontrol 0 0.5 1 1.5 2+
RCT 132 hospitalized COVID-19 patients showing no significant difference in outcomes with zenuzolac (GLS-1027) treatment.
risk of death, 200.2% higher, RR 3.00, p = 0.34, treatment 46, control 44.
risk of death, 195.7% higher, RR 2.96, p = 1.00, treatment 1 of 46 (2.2%), control 0 of 44 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), 360mg.
risk of death, 204.8% higher, RR 3.05, p = 0.49, treatment 1 of 42 (2.4%), control 0 of 44 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), 120mg.
risk of no recovery, 0.7% higher, RR 1.01, p = 0.99, treatment 46, control 44.
risk of no recovery, 43.5% higher, RR 1.43, p = 1.00, treatment 3 of 46 (6.5%), control 2 of 44 (4.5%), 360mg.
risk of no recovery, 47.6% lower, RR 0.52, p = 1.00, treatment 1 of 42 (2.4%), control 2 of 44 (4.5%), NNT 46, 120mg.
hospitalization time, 1.1% lower, relative time 0.99, p = 0.87, treatment 46, control 44.
hospitalization time, 1.1% lower, relative time 0.99, p = 0.90, treatment mean 9.3 (±3.65) n=46, control mean 9.4 (±4.1) n=44, 360mg.
hospitalization time, 1.1% lower, relative time 0.99, p = 0.91, treatment mean 9.3 (±4.2) n=42, control mean 9.4 (±4.1) n=44, 120mg.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kane et al., 11 Apr 2025, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, preprint, 1 author, trial NCT04590547 (history). Contact: dkane@genels.us.
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit